Pfizer accused of "influencing" Canadian doctors with payment for survey

13 February 2006

Global drug giant Pfizer has come under attack in the Canadian daily newspaper the National Post for offering C$275.00 ($239.94) to general practitioners and cardio-logists, in return for their participation in a marketing exercise that is alleged to be "highly unethical."

Doctors are said to have been induced to prescribe a drug for cardiac treatment. The pharmaceutical firm says that the survey does not breach ethical guidelines. Concerns about Canadian doctors being influenced to prescribe a drug against their better judgement because 120 GPs and cardiologists had been reimbursed for their time in taking part in a survey, were unfounded, according to Pfizer.

Colin Rose, a cardiologist based at the Montreal, Canada-based McGill University has promised to hand over his fee to the university where he works, and complained to Canada's pharmaceutical industry trade body, the Research-Based Pharmaceutical Companies (Rx&D).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight